ImmunityBio, based in California, develops immunotherapies against cancer and infectious diseases. Its drug Anktiva is approved in the US for a form of bladder cancer. Further drug candidates are being tested in trials. As of Oct 16, 2026
As of Oct 16, 2026Fact sheet (from the annual report)Biotechnology and vaccines · San Diego, USAfull fact sheet
ImmunityBio is a biotech company that develops and markets immunotherapies against cancer and infectious diseases. Its main product, ANKTIVA, is a fusion protein that activates NK cells and several types of T cells. In the United States, ANKTIVA has been approved since April 2024 with BCG for adults with BCG-unresponsive non-muscle-invasive bladder cancer (carcinoma in situ). There are also approvals in the UK and the Kingdom of Saudi Arabia and, since February 2026, a conditional approval in the European Union. The company is testing ANKTIVA together with standard therapies in other tumor types, for example in lung and pancreatic cancer. For distribution in the European Union and the Middle East, it works with partners such as Accord Healthcare and Cigalah.
Our own calculation from the exchange’s daily candles, as of Oct 26, 2026. “All-time” applies since the start of this series, not to the whole market. Changes in percent; the TradingView chart shows prices. “Today” = change of the last trading day versus the previous day. Not investment advice.
Double bottom · Analysis method
The price of IBRX is currently in no zone of this method. The check runs daily after the market close.
Whether a price will soon reach a zone, you see from Watcher. Plans and pricing
How the zone is formed
What is this? The price has formed two similarly deep lows and broken above the neckline between them. This is seen as a sign that the downward move is ending.
Buy zone: retest of the neckline (up to 1 ATR above it). Stop: just below the second low. Targets: height of the pattern from the neckline (1.0× and 1.618×).
The pattern is valid for at most 15 trading days and expires if the price falls below the stop. This is a calculated analysis, not a forecast and not a call to buy. Risk notice and investment advice
Load chart from TradingView
This transfers data (including your IP address) to TradingView, also to the USA. More in the Privacy policy.
With a free account: save the buy zone shown for yourself (stop and targets from Watcher). It stays visible even if the zone changes later. Log in
· Sign up
Fundamental analysis
SEC filing (10-K, 10-Q)Required reports of listed companies to the US Securities and Exchange Commission (SEC): 10-K is the annual report, 10-Q the quarterly report, 20-F the annual report of foreign companies. We show the figures of the first filing.Example: 10-K for the fiscal year ending Sep 27, 2025, filed on Oct 31, 2025.More in the Academy: Lesson revenue, profit and margin
ImmunityBio · Sector Health Care · amounts in USD
Information only – does not affect our buy zones, not investment advice. Source: SEC filings, As of Feb 23, 2026.
In short
Light green: Revenue grew over 5 years (+299.7% per year), at least as fast as the sector median.
Light red: Loss in the last fiscal year.
Light red: Profit in 0 of 10 fiscal years.
Summarized from the lights below. Describes the reported figures – not a recommendation to buy or sell.
RevenueNet incomeNet margin (below)in USD
−600M−400M−200M0200M
2016Fiscal year 2016 (Jan 1, 2016 – Dec 31, 2016): Revenue 44.0K USD · Net income −120.8M USD · Net margin −274,565.9%
2017Fiscal year 2017 (Jan 1, 2017 – Dec 31, 2017): Revenue 45.0K USD · Net income −96.4M USD · Net margin −214,273.3%
2018Fiscal year 2018 (Jan 1, 2018 – Dec 31, 2018): Revenue 47.0K USD · Net income −96.2M USD · Net margin −204,736.2%
2019Fiscal year 2019 (Jan 1, 2019 – Dec 31, 2019): Revenue 43.0K USD · Net income −65.8M USD · Net margin −152,997.7%
2020Fiscal year 2020 (Jan 1, 2020 – Dec 31, 2020): Revenue 111.0K USD · Net income −92.4M USD · Net margin −83,227.9%
2021Fiscal year 2021 (Jan 1, 2021 – Dec 31, 2021): Revenue 934.0K USD · Net income −346.8M USD · Net margin −37,129.6%
2022Fiscal year 2022 (Jan 1, 2022 – Dec 31, 2022): Revenue 240.0K USD · Net income −416.6M USD · Net margin −173,569.6%
2023Fiscal year 2023 (Jan 1, 2023 – Dec 31, 2023): Revenue 622.0K USD · Net income −583.2M USD · Net margin −93,761.4%
2024Fiscal year 2024 (Jan 1, 2024 – Dec 31, 2024): Revenue 14.7M USD · Net income −413.6M USD · Net margin −2,804.8%
2025Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Revenue 113.3M USD · Net income −351.4M USD · Net margin −310.2%
Q3/23Quarter Q3/23 (Jul 1, 2023 – Sep 30, 2023): Revenue 82.0K USD · Net income −95.6M USD · Net margin −116,563.4%
Q4/23Quarter Q4/23 (Oct 1, 2023 – Dec 31, 2023): Revenue 139.0K USD · Net income −233.4M USD · Net margin −167,907.9% · Q4 derived (year minus 9 months), may be distorted by restatements
Q1/24Quarter Q1/24 (Jan 1, 2024 – Mar 31, 2024): Revenue 40.0K USD · Net income −134.1M USD · Net margin −335,272.5%
Q2/24Quarter Q2/24 (Apr 1, 2024 – Jun 30, 2024): Revenue 1.0M USD · Net income −134.6M USD · Net margin −12,852.3%
Q3/24Quarter Q3/24 (Jul 1, 2024 – Sep 30, 2024): Revenue 6.1M USD · Net income −85.7M USD · Net margin −1,404.0%
Q4/24Quarter Q4/24 (Oct 1, 2024 – Dec 31, 2024): Revenue 7.6M USD · Net income −59.2M USD · Net margin −783.4% · Q4 derived (year minus 9 months), may be distorted by restatements
Q1/25Quarter Q1/25 (Jan 1, 2025 – Mar 31, 2025): Revenue 16.5M USD · Net income −129.6M USD · Net margin −784.9%
Q2/25Quarter Q2/25 (Apr 1, 2025 – Jun 30, 2025): Revenue 26.4M USD · Net income −92.6M USD · Net margin −350.3%
Q3/25Quarter Q3/25 (Jul 1, 2025 – Sep 30, 2025): Revenue 32.1M USD · Net income −67.3M USD · Net margin −209.8%
Q4/25Quarter Q4/25 (Oct 1, 2025 – Dec 31, 2025): Revenue 38.3M USD · Net income −61.9M USD · Net margin −161.8% · Q4 derived (year minus 9 months), may be distorted by restatements
Q1/26Quarter Q1/26 (Jan 1, 2026 – Mar 31, 2026): Revenue 44.2M USD · Net income −632.8M USD · Net margin −1,431.4%
Q2/26Quarter Q2/26 (Apr 1, 2026 – Jun 30, 2026): Revenue 51.2M USD · Net income −230.4M USD · Net margin −449.6%
Q4/25Quarter Q4/25 (Oct 1, 2025 – Dec 31, 2025): Earnings per share not reported separately for Q4
Q1/26Quarter Q1/26 (Jan 1, 2026 – Mar 31, 2026): Earnings per share −0.62 USD
Q2/26Quarter Q2/26 (Apr 1, 2026 – Jun 30, 2026): Earnings per share −0.22 USD
No reported values for “Dividend per share” in this interval.
No reported values for “Dividend per share” in this interval.
Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Revenue 113.3M USD · Net income −351.4M USD · Net margin −310.2%
Key figures with traffic lights
Each light follows a simple, disclosed rule. The comparison is with the sector median Sector medianThe middle value of all companies in a sector: half are above it, half below. Unlike the average, single outliers hardly distort it.Example: Margins 4%, 8%, 10%, 12%, 60% → median 10%, average 18.8%.More in the Academy: Lesson putting the P/E in context of all 63 symbols in the Health Care sector on our list (current members of the S&P 500 and other lists).
Revenue growth
Growth per year (CAGR)The average annual growth rate over several years, as if the value had grown equally strongly every year. Individual good or bad years even out in it.Example: Revenue €100m → €161m in 5 years → (161 ÷ 100) to the power of 1/5 − 1 = 10% per year.More in the Academy: Lesson debt, dividends and growth
Light green: above sector
+299.7%per year, last 5 years
Sector Health Care: median +7.8% (60 symbols)
What does this mean? Revenue: over 5 years it grew by 299.7% per year on average – at least as fast as the median company in the sector (+7.8%).
Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.
Net income (total)
Growth per year (CAGR)The average annual growth rate over several years, as if the value had grown equally strongly every year. Individual good or bad years even out in it.Example: Revenue €100m → €161m in 5 years → (161 ÷ 100) to the power of 1/5 − 1 = 10% per year.More in the Academy: Lesson debt, dividends and growth
Light gray: not computable
–per year, last 5 years
Sector Health Care: median +7.5% (46 symbols)
per share: not computable (loss in the first or last year)
What does this mean? There was a loss in the first or last year. An annual growth rate cannot be calculated meaningfully then.
Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.
What does this mean? Of every 100 USD in revenue there was no profit but a loss of 310.18 USD. Five years ago the margin was −83,227.9%.
Light rule: Green: at least the sector median (without a sector comparison: profit) · Yellow: profit, but below the median · Red: loss.
Debt / equity
Debt-to-equity ratioFinancial debt (loans, bonds) divided by equity. A high value amplifies good and bad years alike. The key figures bar in the chart only uses long-term financial debt.Example: Financial debt €300m, equity €500m → 0.6.More in the Academy: Lesson debt, dividends and growth
Light gray: negative equity
–latest balance sheet
Sector Health Care: median 0.66 (40 symbols)
What does this mean? Equity is negative (e.g. due to share buybacks). A debt-to-equity ratio cannot be formed meaningfully then.
Light rule: Green: at most the sector median · Yellow: up to twice the median · Red: more than twice · Gray: without a sector comparison.
Payout ratio
Payout ratioThe share of profit that a company pays out as a dividend. Above 100% it pays out more than it earns.Example: Dividend €1, earnings per share €2.50 → payout ratio 40%.More in the Academy: Lesson debt, dividends and growth
Light gray: none found
–Dividend / earnings per share
Sector Health Care: median 28% (31 symbols)
What does this mean? The loaded SEC filings of the last two fiscal years contain no dividend per share. Either the company pays none, or it reports it under a different tag.
Light rule: Green: up to 60% of earnings · Yellow: up to 100% · Red: more than earnings or a dividend despite a loss · Gray for real estate (REITs). The sector median is for comparison only.
Profitable years
Profitable yearsHow many of the last fiscal years ended with a profit rather than a loss on the bottom line. The figure shows how consistently a company earns.Example: Profit in 9 of 10 years → one loss year.More in the Academy: Lesson revenue, profit and margin
Light red: 10 loss years
0 of 10fiscal years with a profit
What does this mean? In 0 of the last 10 fiscal years the bottom line showed a profit. 10 years ended with a loss.
Light rule: Green: profit in every year · Yellow: one loss year · Red: several loss years (at least 3 years needed).
Last fiscal year and 13F
Information, not a trading signal · Source: SEC EDGAR
Revenue (FY)
113.3M USD
Revenue vs. prior year
+668.3%
Net income (FY)
−351.4M USD
Net income vs. prior year
–
EPS (FY)
-0.38 USD
13F funds with a position
–
Funds vs. prior quarter
–
Shares held vs. prior quarter
–
Fiscal year to Dec 31, 2025 · 10-K filed Feb 23, 2026 · Price-based figures (P/E, P/S, dividend yield, market cap) only when logged in. · Values as first reported; debt = reported financial debt (US GAAP: long-term).13F: reporting date Jun 30, 2026, 9 tracked funds have filed (latest Aug 14, 2026), filed with up to 45 days of delay. Stock positions only; comparison with Mar 31, 2026 only across funds that filed for both quarters.
All figures as a table
Fiscal years (amounts in USD, per share in USD)
Year
End
Revenue
Net income
Margin
Earnings per share
Dividend per share
Payout
2025
Dec 31, 2025
113.3M
−351.4M
−310.2%
−0.38
–
–
2024
Dec 31, 2024
14.7M
−413.6M
−2,804.8%
−0.62
–
–
2023
Dec 31, 2023
622.0K
−583.2M
−93,761.4%
−1.15
–
–
2022
Dec 31, 2022
240.0K
−416.6M
−173,569.6%
−1.04
–
–
2021
Dec 31, 2021
934.0K
−346.8M
−37,129.6%
−0.89
–
–
2020
Dec 31, 2020
111.0K
−92.4M
−83,227.9%
−0.59
–
–
2019
Dec 31, 2019
43.0K
−65.8M
−152,997.7%
−0.43
–
–
2018
Dec 31, 2018
47.0K
−96.2M
−204,736.2%
–
–
–
2017
Dec 31, 2017
45.0K
−96.4M
−214,273.3%
–
–
–
2016
Dec 31, 2016
44.0K
−120.8M
−274,565.9%
–
–
–
Quarters (amounts in USD, per share in USD)
Quarter
End
Revenue
Net income
Margin
Earnings per share
Dividend per share
Payout
Q2/26
Jun 30, 2026
51.2M
−230.4M
−449.6%
−0.22
–
–
Q1/26
Mar 31, 2026
44.2M
−632.8M
−1,431.4%
−0.62
–
–
Q4/25*
Dec 31, 2025
38.3M
−61.9M
−161.8%
–
–
–
Q3/25
Sep 30, 2025
32.1M
−67.3M
−209.8%
−0.07
–
–
Q2/25
Jun 30, 2025
26.4M
−92.6M
−350.3%
−0.10
–
–
Q1/25
Mar 31, 2025
16.5M
−129.6M
−784.9%
−0.15
–
–
Q4/24*
Dec 31, 2024
7.6M
−59.2M
−783.4%
–
–
–
Q3/24
Sep 30, 2024
6.1M
−85.7M
−1,404.0%
−0.14
–
–
Q2/24
Jun 30, 2024
1.0M
−134.6M
−12,852.3%
−0.20
–
–
Q1/24
Mar 31, 2024
40.0K
−134.1M
−335,272.5%
−0.20
–
–
Q4/23*
Dec 31, 2023
139.0K
−233.4M
−167,907.9%
–
–
–
Q3/23
Sep 30, 2023
82.0K
−95.6M
−116,563.4%
−0.19
–
–
* Q4 derived: fiscal year minus the 9-month value (EPS cannot be derived this way); may be distorted by restatements.
How we calculate: values as first reported to the SEC (later corrections are left out), a fixed order of reporting tags per figure, partial sums are never added up. Growth per year Growth per year (CAGR)The average annual growth rate over several years, as if the value had grown equally strongly every year. Individual good or bad years even out in it.Example: Revenue €100m → €161m in 5 years → (161 ÷ 100) to the power of 1/5 − 1 = 10% per year.More in the Academy: Lesson debt, dividends and growth over 5 years (otherwise 3 years). Quarters are labeled by the calendar quarter in which they end.
Insiders
Insider transactionsExecutives, directors and major shareholders (over 10%) of US companies report their own transactions in their company’s stock to the SEC within two business days (Form 4). Purchases in the market count as more meaningful than sales (often taxes, estate planning).Example: Three executives acquire stock worth a total of 2 million USD within two weeks → “purchases by several insiders”.More in the Academy: Glossary
Jun 30, 2026Selecky ChristobelDirectorOpen-market sale · 10b5-1 plan1,000 shares · $9.0K · SEC
Jun 29, 2026Selecky ChristobelDirectorOpen-market sale · 10b5-1 plan95,722 shares · $862.2K · SEC
Source: mandatory filings with the SEC (Form 4), open-market purchases and sales only. General information, not investment advice.
Trend score +30
Price vs. EMA 50-15
Price vs. EMA 200+15
EMA 50 vs. EMA 200+20
ADX (trend strength)-15
Highs and lows+10
Relative strength+15
Volatility and trend strength
ADX 14 (trend strength)28.5
Rel. strength 60 d+7.1%
ATR ATR (Average True Range)The average range per trading day over the last 14 days. It makes distances comparable, whether a stock costs 10 or 1,000.Example: ATR 2.50 at a price of 100: 0.4 ATR is 1.00, i.e. 1%.More in the Academy: Lesson ATR and moving averages as price values only when logged in.
ImmunityBio Announces Database Lock for Registrational Trial of Locally Delivered, Chemotherapy-Free ANKTIVA® Plus BCG in BCG-Naïve Non-Muscle Invasive Bladder CancerYahoo Finance · Oct 21, 13:30